Seqirus succeeds in opposing Moderna's patent for mRNA vaccine in Australia
Global influenza vaccine company Seqirus’ opposition to US pharma giant Moderna’s patent application over a method for producing high-purity mRNA suitable for use in vaccines has been accepted by a delegate...To view the full article, register now.
Already a subscriber? Click here to view full article